Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Should Play Role In Rx Cost Control, Ex-HHS Assistant Sec. Slater Says

Executive Summary

FDA's mission should be expanded to include a role in controlling the cost of prescription drugs in the U.S., former HHS Assistant Secretary for Health Eve Slater maintains in a Jan. 20 New England Journal of Medicine editorial

You may also be interested in...

FDA Bar Coding Final Rule Sets Two-Year Implementation Timeline

FDA's pharmaceutical bar coding final rule has a shorter implementation timeline than the agency previously proposed

Outcomes Research May Be “Next Frontier” In Drug Development Science

Pharmaceutical outcomes research is the "next frontier" for drug development science, FDA Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman, MD, said at a pharmaceutical outcomes research workshop in Tucson, Ariz. Jan. 23

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts